Anaphylaxis News and Research

RSS

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Today, Biogen Idec will join the global multiple sclerosis (MS) community in celebrating the third annual World MS Day. Biogen Idec continues to be the industry leader in researching and providing groundbreaking therapies for MS. So far in 2011, the company has brought more hope to MS patients through a number of significant milestones.

25 May 2011

Biogen Idec launches educational forum, 'Women in MS'

Biogen Idec today announced the launch of "Women in MS," an educational initiative to address both the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis.

25 May 2011

Children can benefit from The Asthma Management Plans in School Act

New legislation introduced by Rep. Mazie Hirono (D-HI) would provide grants for asthma management programs in schools across the U.S. in a step to ensure the nation's 7.1 million children with asthma have access to care that could save their lives.

12 May 2011

Bayer expands sponsorship agreement with World Federation of Hemophilia

Bayer HealthCare Pharmaceuticals and the World Federation of Hemophilia are announcing a three-year extension of Bayer's sponsorship agreement with WFH.

29 Apr 2011

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.

28 Apr 2011

FDA approves Bayer's new Kogenate FS storage option for hemophilia A treatment

Bayer HealthCare Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved a new storage option for Kogenate FS, antihemophilic factor, now allowing the product to be stored at room temperature for up to one year.

26 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.

21 Apr 2011

EMA CHMP grants positive opinion for Biogen Idec's AVONEX PEN

Biogen Idec announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AVONEX® PEN™ for patients with relapsing multiple sclerosis (MS) and patients with a single demyelinating event.

19 Apr 2011

CHMP adopts EU positive opinion for TYSABRI labeling with anti-JCV antibody status

Biogen Idec and Elan Corporation, plc today announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion for inclusion of an additional risk factor, anti-JC virus (JCV) antibody status, to the product label for TYSABRI in the European Union.

18 Apr 2011

New study finds apparent gaps in restaurant staff's knowledge of food allergy

A new study published in Clinical & Experimental Allergy reveals that there is no association between a restaurant worker's knowledge of food allergy and his or her confidence in being able to provide a safe meal to a food allergic customer.

16 Apr 2011

Lupin grants Salix exclusive worldwide rights to rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of March 31, 2011 Lupin Ltd. granted Salix exclusive worldwide rights (except for India) to exploit Lupin technology and technology jointly developed by Lupin and Salix for all rifaximin products for human use. This agreement expands the collaboration that Salix and Lupin entered into as of September 30, 2009.

6 Apr 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.

6 Apr 2011

Merck enters definitive agreement to acquire Inspire

Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products.

6 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Milk allergy successfully treated with Xolair

A latest study suggests that children with severe milk allergies may be able to rapidly overcome their sensitivities with the help of a biologic drug that helps to quiet an overly aggressive immune response. This is a small study still waiting to be proved in larger populations say researchers.

22 Mar 2011

Researchers to develop house dust mite allergy vaccine that can cure asthma

Monash University researchers are working on a vaccine that could completely cure asthma brought on by house dust mite allergies.

22 Mar 2011

AANMA survey details the impact of asthma and allergies on patients and their families

Today Allergy & Asthma Network Mothers of Asthmatics released a first-of-its-kind survey detailing the impact of asthma and allergies on the people who cope with it every day.

18 Mar 2011

Peanut allergy has a genetic link: Study

A new study suggests that children with a certain gene defect are more likely to develop a peanut allergy. They studied the effect of changes in the gene filaggrin, which helps the skin block out allergens. They noted what has been seen before – the changes in the gene reduce the effectiveness of the barrier, increasing the risk for eczema and asthma.

14 Mar 2011

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011

Anaphylaxis News and Research

Further Reading

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Biogen Idec launches educational forum, 'Women in MS'

Children can benefit from The Asthma Management Plans in School Act

Bayer expands sponsorship agreement with World Federation of Hemophilia

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

FDA approves Bayer's new Kogenate FS storage option for hemophilia A treatment

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

EMA CHMP grants positive opinion for Biogen Idec's AVONEX PEN

CHMP adopts EU positive opinion for TYSABRI labeling with anti-JCV antibody status

New study finds apparent gaps in restaurant staff's knowledge of food allergy

Lupin grants Salix exclusive worldwide rights to rifaximin

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Merck enters definitive agreement to acquire Inspire

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Milk allergy successfully treated with Xolair

Researchers to develop house dust mite allergy vaccine that can cure asthma

AANMA survey details the impact of asthma and allergies on patients and their families

Peanut allergy has a genetic link: Study

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News